Theriva Biologics, Inc. (TOVX) Key Metrics
TOVX valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $9.5M
- Enterprise value
- $3.0M
- P/E (TTM)
- 0.3
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 31.8
- Price / book
- 0.9
- EV / EBITDA
- 1.7
- Dividend yield
- —
- Beta
- 1.19
TOVX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTOVX valuation Price multiples at each fiscal year-end price.
TOVX returns How much profit the business earns on the capital it uses.
TOVX per-share figures Results divided by the shares outstanding at year-end.
TOVX financial health Debt, liquidity and how easily interest is covered.
TOVX efficiency & capital use Working capital cycle and where the cash goes.
TOVX valuation history
TOVX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TOVX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TOVX cash returned to shareholders
TOVX price vs earnings per share
TOVX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $2.6M | — | — | — | $829.4M | — | — | — | — | — |
| Enterprise value | −$7.9M | — | — | — | $763.6M | — | — | — | — | — |
| Price / book | 0.2 | — | — | — | 12.7 | — | — | — | — | — |
| Earnings yield | −988.5% | — | — | — | −1.7% | — | — | — | — | — |
| Free cash flow yield | −653.9% | — | — | — | −1.6% | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | — | 0.0% | — | — | — | — | — |
| Share price at fiscal year-end | $0.21 | $1.75 | $10.75 | $11.37 | $68.05 | $95.75 | $126.72 | $140.00 | $4,445.00 | $6,672.75 |
| Per share | ||||||||||
| Revenue per share | $0.00 | — | — | — | $0.00 | — | — | — | — | — |
| Earnings per share | −$2.08 | — | — | — | −$1.16 | — | — | — | — | — |
| Operating cash flow per share | −$1.37 | — | — | — | −$1.06 | — | — | — | — | — |
| Free cash flow per share | −$1.38 | — | — | — | −$1.06 | — | — | — | — | — |
| Cash per share | $1.08 | — | — | — | $5.52 | — | — | — | — | — |
| Book value per share | $1.27 | — | — | — | $5.37 | — | — | — | — | — |
| Tangible book value per share | −$0.35 | — | — | — | $5.37 | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | $0.00 | — | — | — | — | — |
| Debt per share | $0.22 | — | — | — | $0.13 | — | — | — | — | — |
| Shares outstanding | 12.1M | — | — | — | 12.2M | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −146.6% | −87.3% | −38.9% | −32.8% | −38.6% | −89.7% | −70.0% | −95.9% | — | −274.0% |
| Return on invested capital (ROIC) | −169.8% | −150.3% | −102.2% | −242.4% | — | −692.2% | — | — | — | — |
| Return on assets (ROA) | −68.6% | −56.6% | −28.9% | −27.7% | −36.0% | −78.3% | −64.6% | −54.6% | −73.4% | −102.2% |
| Return on tangible assets | −135.6% | −142.6% | −61.6% | −41.7% | −20.1% | −119.4% | −88.8% | −44.3% | −80.5% | −121.1% |
| Financial health | ||||||||||
| Total debt | $2.6M | $1.6M | $2.2M | $1.7M | $1.5M | $473,000 | $722,000 | — | — | — |
| Cash & short-term investments | $13.1M | $11.6M | $23.2M | $41.8M | $67.3M | $6.2M | $15.0M | $28.9M | $17.1M | $19.1M |
| Net debt | −$10.4M | −$10.0M | −$21.0M | −$40.1M | −$65.8M | −$5.8M | −$14.3M | −$28.9M | −$17.1M | −$19.1M |
| Debt / equity | 0.17 | 0.08 | 0.05 | 0.03 | 0.02 | 0.06 | 0.05 | — | — | — |
| Debt / assets | 0.07 | 0.04 | 0.04 | 0.02 | 0.02 | 0.06 | 0.04 | — | — | — |
| Current ratio | 1.74 | 2.15 | 4.07 | 6.45 | 19.37 | 2.67 | 3.11 | 8.72 | 1.83 | 1.09 |
| Quick ratio | 1.74 | 2.15 | 4.07 | 6.48 | 19.37 | 2.67 | 3.11 | 8.72 | 1.83 | 1.09 |
| Interest coverage | — | — | — | -50.2 | -153.5 | — | — | — | — | — |
| Working capital | $7.5M | $8.7M | $20.7M | $38.5M | $65.3M | $5.0M | $11.2M | $26.1M | $8.2M | $1.8M |
| Invested capital | $5.0M | $9.0M | $18.7M | $14.5M | −$390,000 | $2.3M | $42,000 | $446,000 | −$18.6M | −$15.2M |
| Tangible asset value | −$4.2M | $1.7M | $14.2M | $29.9M | $65.4M | $5.3M | $11.5M | $26.5M | −$3.4M | $2.2M |
| Net current asset value | −$5.4M | −$4,000 | $11.9M | $28.2M | $63.9M | $4.8M | $10.7M | $25.8M | −$4.3M | $1.3M |
| Graham net-net per share | −$0.57 | — | — | — | $5.12 | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | $0 | $288,000 | $0 | — | — | — | — | — |
| Capex / depreciation | 0.32 | 0.01 | 1.50 | 1.36 | 0.16 | 0.04 | 0.04 | 0.03 | 0.87 | 3.62 |
| Efficiency | ||||||||||
| Days of inventory on hand | — | — | — | -314.6 | — | — | 0.0 | — | — | — |
| Days payables outstanding | 3,165.0 | 2,170.0 | 2,277.9 | 979.9 | 2,957.8 | 2,906.4 | 2,546.6 | 2,049.1 | 2,989.3 | 7,446.5 |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | 0.00 | 0.00 |
| Payables turnover | 0.12 | 0.17 | 0.16 | 0.37 | 0.12 | 0.13 | 0.14 | 0.18 | 0.12 | 0.05 |
| Inventory turnover | — | — | — | — | — | — | 240,000.00 | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $3.6M | $2.6M | $1.1M | $231,000 | — | $236,000 | $3,000 | — | $115,500 | $185,000 |
| Average payables | $936,500 | $814,500 | $842,500 | $719,500 | $705,000 | $1.6M | $1.7M | $1.5M | $2.0M | $3.2M |
| Average inventory | — | — | — | −$231,000 | — | — | $1 | — | — | — |
| Intangibles / total assets | 51.3% | 49.1% | 46.1% | 34.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from TOVX's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TOVX valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 0.3. Theriva Biologics earned a return on equity of −146.6% and a return on invested capital of −169.8% in fiscal 2025. It ended the year with $2.6 million of debt and $13.1 million in cash and short-term investments, a net cash position of $10.4 million.
See the TOVX income statement, the TOVX chart for price history, or the TOVX stock overview for the latest quote and news.
TOVX key metrics FAQ
What is Theriva Biologics's P/E ratio?
Theriva Biologics's trailing P/E ratio is 0.3 based on the last twelve months of earnings (as of October 17, 2026). At the end of fiscal 2025 it was —.
What is Theriva Biologics's return on equity?
Theriva Biologics's return on equity (ROE) was −146.6% in fiscal 2025: net income of -$25.2 million on average shareholders' equity of $17.2 million.
What is Theriva Biologics's ROIC?
Theriva Biologics's return on invested capital was −169.8% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Theriva Biologics have?
Theriva Biologics had total debt of $2.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.17 and more cash than debt.
What is Theriva Biologics's free cash flow yield?
Theriva Biologics generated -$16.7 million of free cash flow in fiscal 2025, a free cash flow yield of −653.9% on its market value at year-end ($2.6 million).
What is Theriva Biologics's current ratio?
Theriva Biologics's current ratio was 1.74 at the end of fiscal 2025: current assets were 1.74 times current liabilities.